Bloomberg (5/27, Owram) reports that “the U.S. Food and Drug Administration will hold its first public hearing Friday into how it should regulate CBD products, and it may end up limiting how much of the cannabis compound can be included in food and drinks.” There is currently “pressure on the FDA to act quickly” in deciding how to regulate CBD products, “but the agency has expressed concern that allowing the substance in food, beverages and supplements will lessen the incentive for pharmaceutical companies to conduct clinical research into the health benefits of CBD.” The piece adds that “in announcing the May 31 hearings, then-FDA Commissioner Scott Gottlieb said in a statement that there are ‘open questions about whether some threshold level of CBD could be allowed in foods without undermining the drug approval process or diminishing commercial incentives for further clinical study of the relevant drug substance.’”
Related Links:
— “U.S. Reviews CBD Amid Pressure to Act Quickly, ” Kristine Owram, Bloomberg, May 27, 2019